Literature DB >> 20496013

Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?

Ivano Farinelli1, Ilaria Dionisi, Paolo Martelletti.   

Abstract

Headache is among the most common neurological symptoms in clinical practice. In some cases of episodic migraine, the headache intensifies into a chronic form, defined as chronic migraine (CM) and such a condition encompasses a headache frequency of 15 days/month, with features similar to those of migraine attacks. The assessment of CM in the US general population ranges around 1.3-2%. Migraine progression from an episodic into a chronic form is realized through a period of time involving several months or years, during which an increase attack frequency occurs. Both Topiramate and Onabotulinum toxin A can be considered to be safe as well as effective medications, therefore, representing a treatment choice. Regarding drug abusers, the initial relief step always consists of drug interruption. Only after detoxification can a new prophylaxis therapy be commenced, which otherwise would be useless from the start. The feasible diagnostic setting for the tailored treatment of CM based on the application of pharmacogenomics will allow us in predetermining the efficacy of a single old and new drugs by avoiding abuse due to non-responsivity of the abused drug.

Entities:  

Mesh:

Year:  2010        PMID: 20496013     DOI: 10.1007/s11739-010-0410-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  42 in total

Review 1.  Risk factors for headache chronification.

Authors:  Ann I Scher; Lynn A Midgette; Richard B Lipton
Journal:  Headache       Date:  2008-01       Impact factor: 5.887

2.  Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.

Authors:  Giovanna Gentile; Serena Missori; Marina Borro; Alisa Sebastianelli; Maurizio Simmaco; Paolo Martelletti
Journal:  J Headache Pain       Date:  2010-03-06       Impact factor: 7.277

3.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

4.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

Review 5.  Medication-overuse headache: a worldwide problem.

Authors:  Hans-Christoph Diener; Volker Limmroth
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

6.  Prednisone vs. placebo in withdrawal therapy following medication overuse headache.

Authors:  L Pageler; Z Katsarava; H C Diener; V Limmroth
Journal:  Cephalalgia       Date:  2007-11-26       Impact factor: 6.292

7.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

Review 8.  A narrative review on the management of medication overuse headache: the steep road from experience to evidence.

Authors:  Paolo Rossi; Rigmor Jensen; Giuseppe Nappi; Marta Allena
Journal:  J Headache Pain       Date:  2009-10-03       Impact factor: 7.277

Review 9.  New drugs for migraine.

Authors:  Lars Jacob Stovner; Erling Tronvik; Knut Hagen
Journal:  J Headache Pain       Date:  2009-10-01       Impact factor: 7.277

Review 10.  Topiramate in migraine progression.

Authors:  Luigi Ruiz; Delfina Ferrandi
Journal:  J Headache Pain       Date:  2009-10-17       Impact factor: 7.277

View more
  6 in total

1.  An emerging problem in clinical practice: how to treat chronic headache patients.

Authors:  Luigi Alberto Pini
Journal:  Intern Emerg Med       Date:  2010-12-07       Impact factor: 3.397

Review 2.  Anti-CGRP monoclonal antibodies in migraine: current perspectives.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Martina Curto; Andrea Negro; Raffaele Costantini; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2016-06-23       Impact factor: 3.397

3.  Dispute settlement understanding on the use of Botox in chronic migraine.

Authors:  Paolo Martelletti
Journal:  J Headache Pain       Date:  2011-02       Impact factor: 7.277

4.  The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine.

Authors:  Paolo Martelletti
Journal:  J Headache Pain       Date:  2018-01-10       Impact factor: 7.277

5.  Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial.

Authors:  Paolo Rossi; Jessica Veronica Faroni; Cristina Tassorelli; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2013-02-08       Impact factor: 7.277

6.  Analysis of risk factors for medication-overuse headache relapse: a clinic-based study in China.

Authors:  Zhihui Yan; Yuan Chen; Chunfu Chen; Congcong Li; Xiaojun Diao
Journal:  BMC Neurol       Date:  2015-09-17       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.